Abstract:
Androgen receptor (AR) regulates gene expression and has strong implications in the disease progression of prostate cancer (PCa) and benign prostate hyperplasia (BPH). The current investigation created a reporter cell line and assays relevant to PCa, which allow detection of the AR activity and response of PCa cells to a candidate compound. Use of this cell line and reporter assay, we found inhibition of AR activity by anti-androgens, including bicalutamide, flutamide, and nilutamide, presumably through direct competition of the hormone binding to the receptor, and by kinase inhibitor against IKKα (e.g. wedelactone) indirectly through intervention of signaling and molecular interaction between AR and IKKα. Prostate cancer has been a leading cause of cancer death in developed countries. Hormonal therapies that reduce androgen levels or stop AR binding to androgens are current remedy to extra-glandular PCa. However, limitation of hormone therapy is that cancer often escapes androgen dependence and restraint by anti-androgen. Once become androgen-independent PCa, no alternative treatment is valid at present to improve patients’ survival. We identified a novel signal requirement for AR. By targeting the revealed signaling, we demonstrate promising effects of a natural compound on preventing cancer cell growth. This study may initiate development of a new remedy for prostate cancer.
Fields of Application:
1.Use of the 22Rv/103E cell line and reporter gene assay allows functional detection of hormonal effect (agonists and enhancers) to the AR or inhibitors of hormone-receptor (antagonists and suppressors). 2.Using the 22Rv/103E cell line and reporter gene assay can be implemented to detect AR activity in vitro in cell culture for high throughput screening or in vivo in animal model.
Advantages when compared to the existing technologies:
The reporter cell line assay combines prostate cancer cells of clinical relevance and gene promoter assay of the most reliable therapeutic biomarker (PSA). Other existing assays measure either the hormone-dependent AR interaction with a specific coactivator/corepressor or the AR activity in clinically irrelevant promoters (MMTV or synthetic AR responsive promoter). As compared, both features of the current technology provide the preclinical tests with higher success rate in the future clinical test.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
